［1］    Bando H, Tsukada Y, Inamori K, et al. Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer ［J］. Clin Cancer Res, 2022, 28(6): 1136-1146.DOI:10.1158/1078-0432.CCR-21-3213.
［2］    Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors ［J］. Trends in cancer, 2023, 9(7): 543-553. DOI:10.1016/j.trecan.2023.04.002.
［3］    Chamoto K, Yaguchi T, Tajima M, et al. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1 ［J］. Nat Rev Immunol, 2023, 23(10): 682-695. DOI:10.1038/s41577-023-00867-9.
［4］    Ludford K, Ho WJ, Thomas JV, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors ［J］. J Clin Oncol, 2023, 41(12): 2181-2190. DOI:10.1200/jco.22.01351.
［5］    Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors ［J］.  Nat Rev Clin Oncol, 2020, 17(12): 725-741. DOI:10.1038/s41571-020-0413-z.
［6］    Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma ［J］. J Clin Oncol, 2017, 35(7): 785-792. DOI:10.1200/jco.2015.66.1389.
［7］    Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer ［J］. JAMA Oncol, 2020, 6(6): 865-871. DOI:10.1001/jamaoncol.2020.0726.
［8］    Takada K, Takamori S, Brunetti L, et al. Impact of neoadjuvant immune checkpoint inhibitors on surgery and perioperative complications in patients with non-small-cell lung cancer: A systematic review ［J］.  Clin Lung Cancer, 2023, 24(7): 581-590.e5. DOI:10.1016/j.cllc.2023.08.017.
［9］    邱小原, 孙丽婷, 王晨童, 等. 直肠癌新辅助免疫治疗相关不良反应分析:一项全国多中心回顾性研究［J］. 中国实用外科杂志, 2024, 44(7):787-792. DOI: 10.19538/j.cjps.issn1005-2208.2024.07.14.
［10］    中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国老年医学学会皮肤医学分会. 免疫检查点抑制剂相关皮肤不良反应诊治中国专家共识（2024版） ［J］. 中华医学杂志, 2024, 104(20): 1790-1803. DOI:10.3760/cma.j.cn112137-20240112-00091.
［11］    Phillips GS, Wu J, Hellmann MD, et al. Treatment outcomes of immune-related cutaneous adverse events ［J］. J Clin Oncol, 2019, 37(30): 2746-2758. DOI:10.1200/jco.18.02141.
［12］    Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC ［J］. Cancer immunology research, 2018, 6(9): 1093-1099. DOI:10.1158/2326-6066.Cir-17-0755.
［13］    Lee H, Hodi FS, Giobbie-Hurder A, et al. Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy ［J］. Cancer Immunol Res, 2017, 5(12): 1133-1140. DOI: 10.1158/2326-6066.CIR-17-0208.
［14］    De Filette J, Andreescu CE, Cools F, et al. A systematic review and Meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors ［J］. Horm Metab Res, 2019, 51(3): 145-156. DOI: 10.1055/a-0843-3366.
［15］    André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer ［J］. N Engl J Med, 2020, 383(23): 2207-2218. DOI: 10.1056/NEJMoa2017699.
［16］    Cohen R, Bennouna J, Meurisse A, et al. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase Ⅱ study ［J］.  J Immunother Cancer, 2020, 8(2): e001499.DOI: 10.1136/jitc-2020-001499.
［17］    Hattersley R, Nana M, Lansdown AJ. Endocrine complications of immunotherapies: A review ［J］. Clin Med (Lond), 2021, 21(2): e212-e222. DOI: 10.7861/clinmed.2020-0827.
［18］    Mcmillen B, Dhillon MS, Yong-Yow S. A rare case of thyroid storm ［J］. BMJ Case Rep, 2016, 2016: bcr2016214603. DOI:10.1136/bcr-2016-214603.
［19］    Kurokawa R, Ota Y, Gonoi W, et al. MRI findings of immune checkpoint inhibitor-induced hypophysitis: possible association with fibrosis ［J］. Am J Neuroradiol, 2020, 41(9): 1683-1689. DOI:10.3174/ajnr.A6692.
［20］    Van Der Leij S, Suijkerbuijk KPM, Van Den Broek MFM, et al. Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis ［J］. Front Endocrinol (Lausanne), 2024, 15：1400841. DOI:10.3389/fendo.2024.1400841.
［21］    Tan MH, Iyengar R, Mizokami-Stout K, et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports ［J］. Clin Diabetes Endocrinol, 2019, 5: 1. DOI:10.1186/s40842-018-0073-4.
［22］    Iglesias P, Sánchez JC, Díez JJ. Isolated ACTH deficiency induced by cancer immunotherapy: A systematic review ［J］. Pituitary, 2021, 24(4): 630-643. DOI:10.1007/s11102-021-01141-8.
［23］    Kennedy OJ, Ali N, Lee R, et al. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study ［J］.  Eur J Cancer, 2024, 202: 113949. DOI:10.1016/j.ejca.2024.113949.
［24］    Stelmachowska-Banas M, Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: An updated review ［J］. Endocr Connect, 2020, 9(10): R207-R228. DOI:10.1530/EC-20-0342.
［25］    Ferrari S M, Fallahi P, Elia G, et al. Autoimmune endocrine dysfunctions associated with cancer immunotherapies ［J］. Int J Mol Sci, 2019, 20(10):2560. DOI: 10.3390/ijms20102560.
［26］    Arima H, Iwama S, Inaba H, et al. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine Society ［J］. Endocr J, 2019, 66(7): 581-586. DOI: 10.1507/endocrj.EJ19-0163.
［27］    Higham CE, Olsson-Brown A, Carroll P, et al. Society for Endocrinology Endocrine Emergency Guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy ［J］. Endocr Connect, 2018, 7(7): G1-G7. DOI: 10.1530/EC-18-0068.
［28］    Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ［J］. Ann Oncol, 2022, 33(12): 1217-1238. DOI: 10.1016/j.annonc.2022.10.001.
［29］    Miah A, Tinoco G, Zhao S, et al. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival ［J］. J Cancer Res Clin Oncol, 2022, 149(5): 2235-2242. DOI: 10.1007/s00432-022-04340-3.
［30］    Da Cunha T, Wu GY, Vaziri H. Immunotherapy-induced hepatotoxicity: A review ［J］. J Clin Transl Hepatol, 2022, 10(6): 1194-1204. DOI:10.14218/JCTH.2022.00105.
［31］    Dougan M, Wang Y, Rubio-Tapia A, et al. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: Expert review［J］. Gastroenterology, 2021, 160(4): 1384-1393. DOI: 10.1053/j.gastro.2020.08.063.
［32］    Chen K, He J, Xu J, et al. Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and Meta-analysis ［J］. Front Oncol, 2023, 13：1088741. DOI: 10.3389/fonc.2023.1088741.
［33］    Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology ［J］.  J Natl Compr Canc Netw, 2022, 20(4): 387-405. DOI:10.6004/jnccn.2022.0020.
［34］    Burri E, Mangana J, Cheng PF, et al. Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids ［J］.  J Immunother Cancer, 2024, 12(7): e008074. DOI： 10.1136/jitc-2023-008074.
［35］    Moi L, Bouchaab H, Mederos N, et al. Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis ［J］. J Thorac Oncol, 2021, 16(2): 318-326. DOI:10.1016/j.jtho.2020.09.007.
［36］    Shatila M, Zhang HC, Shirwaikar Thomas A, et al. Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events ［J］. J Immunother Cancer，2024，12(11): e009742. DOI：10.1136/jitc-2024-009742.
［37］    Kroner PT, Mody K, Farraye FA. Immune checkpoint inhibitor-related luminal GI adverse events ［J］. Gastrointest Endosc, 2019, 90(6): 881-892. DOI: 10.1016/j.gie.2019.09.009.
［38］  Moraitis I, Guiu J, Rubert J. Gut microbiota controlling radiation-induced enteritis and intestinal regeneration ［J］. Trends Endocrinol Metab, 2023, 34(8): 489-501. DOI: 10.1016/j.tem.2023.05.006.
［39］    Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis ［J］. Inflamm Bowel Dis, 2018, 24(8): 1695-1705. DOI:10.1093/ibd/izy104.
［40］    Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management ［J］. ESMO Open, 2018, 3(1): e000278. DOI:10.1136/esmoopen-2017-000278.
［41］    Wang H, Guo X, Zhou J, et al. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis ［J］. Thorac Cancer, 2020, 11(1): 191-197. DOI:10.1111/1759-7714.13240.
［42］    Reuss JE, Kunk PR, Stowman AM, et al. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: A case report & review of the literature ［J］. J Immunother Cancer, 2016, 4：94. DOI:10.1186/s40425-016-0199-9.
［43］    Kalisz KR, Ramaiya NH, Laukamp KR, et al. Immune checkpoint inhibitor therapy-related pneumonitis: Patterns and management ［J］. Radiographics, 2019, 39(7): 1923-1937. DOI:10.1148/rg.2019190036.
［44］    Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update ［J］. J Clin Oncol, 2021, 39(36): 4073-4126. DOI:10.1200/jco.21.01440.
［45］    Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: A narrative review ［J］. Am J Nephrol, 2017, 45(2): 160-169. DOI:10.1159/000455014
［46］    Hu F, Zhai Y, Yuan L, et al. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database ［J］. Cancer Med, 2021, 10(24): 8754-8762. DOI:10.1002/cam4.4343.
［47］    Carrasco J, Schröder D, Sinapi I, et al. 397P R-IMMUNE interim analysis: A phase Ⅰb/Ⅱ study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with localized rectal cancer ［J］. Ann Oncol, 2021, 32（suppl5）：s537. DOI:10.1016/j.annonc.2021.08.919.
［48］    Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade ［J］. Curr Probl Cancer, 2017, 41(2): 100-110. DOI:10.1016/j.currproblcancer.2016.12.004.
［49］    Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated aki: A multicenter study ［J］. J Am Soc Nephrol, 2020, 31(2): 435-446. DOI:10.1681/ASN.2019070676.
［50］    Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study［J］. Lancet Oncol, 2018, 19(12): 1579-1589. DOI:10.1016/S1470-2045(18)30608-9.
［51］    Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors ［J］. J Am Coll Cardiol, 2018, 71(16): 1755-1764. DOI: 10.1016/j.jacc.2018.02.037.
［52］    Reuben A, Petaccia De Macedo M, Mcquade J, et al. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab ［J］. Oncoimmunology, 2017, 6(12): e1361097. DOI:10.1080/2162402X.2017.1361097.
［53］    de Perna ML, Rigamonti E, Zannoni R, et al. Immune checkpoint inhibitors and cardiovascular adverse events ［J］. ESC Heart Fail，2025 Apr 10. Epub ahead of print.DOI: 10.1002/ehf2.15281. ［］.
［54］    Tan S, Qi C, Zeng H, et al. Steroid-refractory myocarditis induced by immune checkpoint inhibitor responded to infliximab：Report of two cases and literature review ［J］. Cardiovasc Toxicol, 2024，24(11): 1174-1191. DOI：10.1007/s12012-024-09918-6.
［55］    Michot JM, Lazarovici J, Tieu A, et al. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?［J］. Eur J Cancer，2019，122：72-90. DOI:10.1016/j.ejca.2019.07.014.
［56］    Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events ［J］. J Immunother Cancer, 2021, 9(6): e002435. DOI: 10.1136/jitc-2021-002435.
［57］    秦叔逵，李进，梁军. 中国临床肿瘤协会(CSCO)免疫检查点抑制剂相关的毒性管理指南［M］. 北京: 人民卫生出版社，2019.
［58］    Moore DC, Elmes JB, Arnall JR, et al. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review ［J］. Int Immunopharmacol，2024，129: 111606. DOI: 10.1016/j.intimp.2024.111606.
［59］    Cappelli LC, Gutierrez AK, Bingham CO 3rd, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature ［J］. Arthritis Care Res（Hoboken），2017，69(11)：1751-1763. DOI:10.1002/acr.23177.
［60］    Cano-Cruz LG, Barrera-Vargas A, Mateos-Soria A, et al. Rheumatological adverse events of cancer therapy with immune checkpoint inhibitors ［J］. Arch Med Res, 2022, 53(2): 113-121. DOI:10.1016/j.arcmed.2021.09.004.
［61］    Allenbach Y, Anquetil C, Manouchehri A, et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities ［J］. Autoimmun Rev, 2020, 19(8): 102586. DOI:10.1016/j.autrev.2020.102586.
［62］    Tian Y, Gao A, Wen Q, et al. Immune-related neurological toxicities of PD-1/PD-L1 inhibitors in cancer patients: A systematic review and Meta-analysis ［J］. Front Immunol, 2020, 11：595655. DOI:10.3389/fimmu.2020.595655.
［63］   Marini A, Bernardini A, Gigli GL, et al. Neurologic adverse events of immune checkpoint inhibitors: A Systematic Review ［J］. Neurology, 2021, 96(16): 754-766. DOI:10.1212/wnl.0000000000011795.
［64］    Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps ［J］. Nat Rev Neurol, 2019, 15(11): 671-683. DOI:10.1038/s41582-019-0250-9.
［65］    Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan ［J］. Neurology, 2017, 89(11): 1127-1134. DOI:10.1212/wnl.0000000000004359.
［66］    Li Y, Zhang X, Zhao C. Guillain-Barré syndrome-like polyneuropathy associated with immune checkpoint inhibitors: A Systematic review of 33 cases ［J］. Biomed Res Int, 2021, 2021：9800488. DOI:10.1155/2021/9800488.
［67］    Whittam DH, Tallantyre EC, Jolles S, et al. Rituximab in neurological disease: principles, evidence and practice ［J］. Pract Neurol, 2019, 19(1): 5-20. DOI:10.1136/practneurol-2018-001899.